Navigation Links
Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin
Date:4/12/2011

ic intervention but are not candidates for curative surgical resection. The effectiveness of Afinitor is based on an analysis of change in SEGA volume. Clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been shown. Novartis has submitted marketing applications for everolimus for this use to the European Medicines Agency (EMA) and the Swiss Agency for Therapeutic Products (Swissmedic), and additional regulatory submissions are under way worldwide.

Afinitor is available in the US in 2.5 mg, 5 mg and 10 mg tablet strengths. With once-daily dosing, Afinitor targets mTOR, a protein that acts as an important regulator of tumor cell division, blood vessel growth and cell metabolism.

In the US, everolimus is available in different dosage strengths for the non-oncology patient population under the trade name Zortress® for the prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a kidney transplant. In the EU, everolimus is available in different dosage strengths under the trade name Certican® for the prevention of organ rejection in heart and kidney transplant recipients.

Everolimus is exclusively licensed to Abbott and sublicensed to Boston Scientific for use in drug-eluting stents.

Not all indications are available in every country. As an investigational compound the safety and efficacy profile of everolimus has not yet been established in pancreatic or any other type of NET. Access to everolimus outside of the approved indications has been carefully controlled and monitored in clinical trials designed to better understand the potential benefits and risks of the compound. Because of the uncertainty of clinical trials, there is no guarantee that everolimus will become commercially available for pancreatic or any other type of NET or any additional indications anywhere in the world.

Important Safety Information for Afini
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
2. Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
3. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
4. Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients
5. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
6. Final Approval of Novartis Gender Discrimination Settlement Slated for November 19
7. Study in NEJM Shows Novartis Drug Afinitor® Reduces Size of SEGAs, Benign Brain Tumors Associated with Tuberous Sclerosis
8. VIDEO from thenewsmarket.com and Novartis: Novartis drug Afinitor® Approved by FDA as First Medication for Children and Adults With a Benign Brain Tumor Associated With Tuberous Sclerosis
9. Novartis to Expand Global Research Headquarters in Cambridge, MA
10. VIDEO From thenewsmarket.com and Novartis: Phase III Data Show That Novartis Meningococcal Vaccine Menveo® Demonstrated Robust Immunogenicity in Infants
11. Analysis Shows Novartis Drug TOBI® Associated With Reduced Mortality in Cystic Fibrosis Patients With Common Lung Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... LONDON , December 24, 2014 ... grow at an average rate of 8.1%. The US ... Hip, knee and spine surgeries are the common orthopedic ... they have a lower penetration. Increased number of product ... composites. Non-metallic orthopedic devices have gained popularity in the ...
(Date:12/24/2014)... , Dec. 23, 2014  Advanced Medical Isotope ... engaged primarily in the development of brachytherapy devices ... today announced that it has filed a ... Drug Administration ("FDA") for marketing clearance for its ... of the U.S. Food, Drug and Cosmetic Act ...
(Date:12/24/2014)... Dec. 23, 2014   Synageva BioPharma Corp. ... company developing therapeutic products for rare disorders, today ... of the Marketing Authorization Application (MAA) for sebelipase ... the company,s request for accelerated assessment, which has ... time.   The MAA, and the ...
Breaking Medicine Technology:Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
... Endothelial Dysfunction, Conference Call and Webcast to ... CET), NOVATO, Calif., Oct. 15 BioMarin,Pharmaceutical ... from its Phase,2a multi-center, open-label, dose-escalation clinical study ... designed to evaluate whether 6R-BH4,can improve the endothelial ...
... for physicians, NATICK, Mass. and WASHINGTON, Oct. ... today announced results from an analysis,of the HORIZONS ... the,Cardiovascular Research Foundation (CRF) with research grant support ... MDCO ) is designed to,determine the safety and ...
Cached Medicine Technology:BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease 2BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease 3BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease 4BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease 5BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease 6HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS(R) Drug-Eluting Stents in Heart Attack Patients 2HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS(R) Drug-Eluting Stents in Heart Attack Patients 3HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS(R) Drug-Eluting Stents in Heart Attack Patients 4
(Date:12/25/2014)... 2014 Plugin creators from Pixel Film ... fully customizable business presentation tool made specifically for ... 5k business tool, users can now display their stats ... Pixel Film Studios. “ProFire 5k gives users a multiple ... professionalism to a presentation” , Pixel Film Studios takes ...
(Date:12/25/2014)... 2014 Each year trauma accounts for ... hospital admissions across the nation (according to the ... CDC’s National Hospital Ambulatory Medical Care Survey collected ... in 2010. They estimated that there were between 3.5 ... a primary diagnosis of broken bone or fracture. ...
(Date:12/24/2014)... AlignLife of Wauwatosa loves helping ... items. During the holiday season, AlignLife looks forward to their ... says Dr. Sara Mahalko-Leonhardt, owner of AlignLife. "It brings our ... that we are able to give kids toys for Christmas ... for the generosity of our patients." , The 70 toys ...
(Date:12/24/2014)... Epigenetics finds applications in a large number of fields ... biology, and research for metabolic and genetic disorders. It ... used techniques for the discovery and development of cancer ... rapidly growing worldwide. In 2012, there were 14.1 million ... million people living with cancer (within five years of ...
(Date:12/24/2014)... Recently, iFitDress.com, a famous dress manufacturer and retailer, ... $150 . All these items are brand new; they are ... been updated with the new range of high quality prom ... All iFitDress.com’s designs are made according to the latest trends. ... Every outfit from the company is handpicked by skilled tailors. ...
Breaking Medicine News(10 mins):Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Many Prom Dresses under 150 from Well-known Dress Manufacturer iFitDress.com 2
... The American Dietetic Association commended Congress and ... State Children,s Health Insurance Program into law.The $32.6 ... President Bush in 2007, expands government health coverage ... services, but who also cannot afford private medical ...
... Manufacturers of America (PhRMA) President and CEO Billy ... State Children,s Health Insurance Program Reauthorization Act:"President Obama,s ... Children,s Health Insurance Program (SCHIP) marks a tremendous ... and, indeed, for all Americans -- for we ...
... developed deposits, study finds , , WEDNESDAY, Feb. 4 (HealthDay ... sickened more than 50,000 kids last fall resulted in ... developing kidney problems, according to just-released Beijing research on ... in Taiwan and 10 percent of those who drank ...
... coverageWASHINGTON, Feb. 4 "This afternoon, Congress put ... the State Children,s Health Insurance Program (SCHIP). ... delivers critical help to modest-income families struggling to ... Dr. Jane L. Delgado, President and CEO of ...
... 4 , WHAT: , ... with members of the cast,of Broadway,s Tony Award-winning best musical ... 6, 2009 , WHO: , ... stories of women making,heart-healthy choices and inspiring others with their ...
... 04 February 2009 The journal Medical ... announced the winner of the 2008 David Horrobin Prize ... Jan van der Linden from the Karolinska Institute in ... risk of surgical site infection" was judged to best ...
Cached Medicine News:Health News:American Dietetic Association Commends Congress and President for Passage of State Children's Health Insurance Legislation 2Health News:PhRMA Statement on Expansion of SCHIP 2Health News:Tainted China Formula Caused High Rate of Kidney Stones in Kids 2Health News:Tainted China Formula Caused High Rate of Kidney Stones in Kids 3Health News:Final House Vote on SCHIP Delivers Peace of Mind to America's Families 2Health News:Go Red Corazon(R) 'Que nos dice el corazon?' National Casting Call Event 2
... The Sony DXC-S500 consists of 2-piece body, ... & light weight and built-in Peltier cooling devices, ... 3.5 inch LCD monitor. CCU incorporates IEEE1394 interface ... equipped with PCMCIA card slot for storing images ...
Sony DSR-20MD is the right choice If you need digital recording capability. It accepts both s-video and composite inputs....
The VISERA Multi-Specialty Digital Imaging Platform is the world's first integrated system of digital rigid, deflectable tip and flexible videoscopes for use in operating room endosurgery as well as ...
... Digital solutions for clinical image management. ... and patient-data management system derived from ... digital technology to capture, organize, and ... text data with minimum effort. Can ...
Medicine Products: